Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)

RADNOR, PA - March 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQMRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 5, 2025.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Options

SAN DIEGO, March 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025. Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit. Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai and certain of Maravai’s top executives with violations of the Securities Exchange Act of 1934.

Law Offices of Howard G. Smith reminds investors of the upcoming May 5, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”).

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQMRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 5, 2025.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - March 6, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQMRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 5, 2025.

Glancy Prongay & Murray LLP reminds investors of the upcoming May 5, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”).

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”). Investors have until May 5, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Maravai Lifesciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities during the period from August 7, 2024, through February 24, 2025 (“the Class Period”). Investors have until May 5, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQMRVI) between August 7, 2024 and February 24, 2025. Maravai is a life sciences company which provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Maravai LifeSciences To Contact Him Directly To Discuss Their Options

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Maravai investors have until May 5, 2025 to file a lead plaintiff motion.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQMRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nelson v. Maravai LifeSciences Holdings, Inc., et al., Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) and reminds investors of the May 5, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nelson v. Maravai LifeSciences Holdings, Inc., et al., Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) on behalf of Maravai stockholders. Our investigation concerns whether Maravai has violated the federal securities laws and/or engaged in other unlawful business practices.

Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQMRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) investors concerning the Company’s possible violations of the federal securities laws.

Shares of Maravai LifeSciences Holdings, Inc. (“Maravai LifeSciences”) plunged over 21% in intraday trading on Tuesday, February 25, 2025, after the company disclosed it would be delaying its 2024 earnings release. The company delayed the earning release and investor call, stating that it needs additional time to complete an assessment of disclosure controls and internal controls over financial reporting. Gibbs Law Group is investigating a potential Maravai LifeSciences (NASDAQMRVI) Securities Class Action Lawsuit on behalf of shareholders who lost money in Maravai LifeSciences Holdings.

Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQMRVI) on behalf of investors concerning the Company’s possible violations of federal securities laws.